





Syndromic Testing: The Right Test, The First Time.




Don't Guess, Know.

Many infectious diseases present with similar signs and symptoms. Traditional targeted diagnostics limit testing to only the pathogens most commonly associated with a clinical syndrome. Because this testing method is so narrowly defined, it can leave many infections undiagnosed and may lead to additional downstream testing, patient dissatisfaction, and compromised patient care.

BioFire's syndromic approach to infectious disease diagnostics helps quickly identify pathogens, greatly reduces the guesswork in diagnostics, may increase patient satisfaction, can help improve patient care, and helps make the world a healthier place.

Choose the right test, the first time. Choose syndromic testing from BioFire.

Traditional Testing

















Syndromic Testing















¹Brendish NJ, et al. Lancet Respir Med. 2017 May;5(5):401-411.



The Fastest Way to Better Results.



Faster Results

With about an hour turnaround time, BioFire's syndromic testing helps clinicians make vital decisions regarding admission, isolation, cohorting, antiviral or antibiotic therapy, and additional diagnostic testing.



Better Results

By harnessing the power of syndromic testing, labs can increase the probability of identifying a pathogen in patients with symptoms of an infectious disease. Each BioFire® FilmArray® Panel increases the capability of detecting co-infections and may result in shorter length of stay and improved downstream savings.

"FilmArray from BioFire has massively influenced the way we now manage our patients and infection control situations. For example, rapid diagnosis of whooping cough [B. pertussis on BioFire® Respiratory 2.1 plus Panel] has enabled us to initiate effective treatment and infection control measures within hours of patient's arrival to the hospital. Previously, a result from reference lab would typically take three to four days."

Dr. Mitul Patel

Consultant Microbiologist Birmingham Children's Hospital, UK



Syndromic Testing Streamlines Laboratory Processes.

BioFire products can be used by any technician, on any shift, at any time. This helps hospitals provide the same standard of care 24/7 and removes the need to delay or send out samples for additional testing.



Fast

With a run time of about an hour, syndromic testing enables laboratories to provide answers to physicians in a clinically actionable time frame.



Easy

BioFire's syndromic approach is easy, and test preparation requires only two minutes of hands-on time. Results are given in a positive or negative report for each pathogen from a broad test menu.




Comprehensive

Syndromic testing eliminates serial testing that can be frustrating and timeconsuming for laboratories. It consolidates quality control and proficiency testing as well as minimizes the time required to keep and maintain multiple instruments.

The BioFire® FilmArray® Torch:

The most advanced syndromic testing.



Scalable configuration for customized throughput from 1 to 12 modules.



Intuitive

Provides faster input and navigation through an optimized user experience with a touchscreen interface, integrated barcode scanner, and intuitive instrument control.



Access

Improved testing and laboratory productivity with random and continuous access sample loading.




Connectivity

Makes data management automated and efficient through the BioFire® FilmArray® Link Technology that can seamlessly integrate into Laboratory Information System (LIS).




Radically Reduced Footprint

The BioFire® Torch offers the most scalable system with the same footprint.²



¹Calculations based on running the BioFire® Respiratory 2.1 *plus* Panel over a 24-hour day. ²In comparison to existing BioFire® FilmArray® Systems.



Fast Answers With BioFire Syndromic Panels.

Comprehensive Panels Offer Better Diagnostics

Comprehensive panels take out the guesswork. Each BioFire® Panel targets an infectious disease syndrome by combining a broad grouping of probable pathogenic causes into a single test.

The US FDA-cleared and CE-marked BioFire Panels test for viruses, bacteria, parasites, yeast, and antimicrobial resistance genes.



Respiratory 2.1 plus Panel



Pneumonia plus Panel



Gastrointestinal Panel



Meningitis/Encephalitis Panel



Blood Culture Identification 2 Panel



Bone and Joint Infection Panel Investigational Use Only.

Product availability varies by country. Consult your bioMérieux representative.



Sample Type: 300µL of nasopharyngeal swab CE-marked

23 Targets in One Test

The BioFire® Respiratory 2.1 *plus* (RP2.1 *plus*) Panel identifies the most common viral and bacterial pathogens—including SARS-CoV-2—that cause respiratory tract infections, which can present with nearly indistinguishable symptoms. An unprecedented run time of about 45 minutes enables higher efficiency and throughput on the BioFire® 2.0 and the BioFire® Torch Systems, and offers faster results to clinicians, potentially enabling better-informed diagnosis and treatment of patients. Higher overall sensitivity across a broader spectrum of pathogens means the BioFire RP2.1 *plus* Panel offers the world the fastest way to better results in the detection of respiratory pathogens.

Panel Menu

VIRUSES

Adenovirus
Coronavirus 229E
Coronavirus HKU1
Coronavirus NL63
Coronavirus OC43
Middle East Respiratory
Syndrome Coronavirus (MERS-CoV)
Severe Acute Respiratory Syndrome
Coronavirus 2 (SARS-CoV-2)
Human Metapneumovirus

Human Rhinovirus/Enterovirus

Influenza A
Influenza A/H1
Influenza A/H1-2009
Influenza A/H3
Influenza B
Parainfluenza Virus 1
Parainfluenza Virus 2


Parainfluenza Virus 3

Parainfluenza Virus 4

Respiratory Syncytial Virus

BACTERIA

Bordetella parapertussis Bordetella pertussis Chlamydia pneumoniae Mycoplasma pneumoniae





Sample Type: Sputum (including ETA) and BAL (including mini-BAL) CE-marked and US FDA-cleared

34 Targets in One Test

The BioFire Pneumonia *plus* Panel tests for 27 of the most common bacterial and viral pathogens associated with various types of community/hospital-acquired pneumonia, along with 7 antimicrobial resistance genes. Quickly identifying the probable causative agent can help a healthcare provider determine how best to treat a lower respiratory tract infection.

Panel Menu

BACTERIA

Semi-Quantitative Bacteria

Acinetobacter calcoaceticusbaumannii complex

Enterobacter cloacae complex

Escherichia coli

Haemophilus influenzae

Klebsiella aerogenes

Klebsiella oxytoca

Klebsiella pneumoniae group

Moraxella catarrhalis

Proteus spp.

Pseudomonas aeruginosa Serratia marcescens

Staphylococcus aureus Streptococcus agalactiae

Streptococcus pneumoniae

Streptococcus pyogenes

ATYPICAL BACTERIA Qualitative Bacteria

Chlamydia pneumoniae Legionella pneumophila

Mycoplasma pneumoniae

VIRUSES

Adenovirus Coronavirus

Human Metapneumovirus

Human Rhinovirus/Enterovirus

Influenza A

Middle East Respiratory Syndrome Coronavirus (MERS-CoV)

Influenza B Parainfluenza Virus

Respiratory Syncytial Virus

ANTIMICROBIAL RESISTANCE GENES

Carbapenemases

IMP KPC

NDM OXA-48-like


. // 8. //

VIM

ESBL CTX-M

Methicillin Resistance

mecA/C and MREJ (MRSA)





Sample Type: 200 μ L stool collected in Cary Blair transport medium CE-marked and US FDA-cleared

22 Targets in One Test

The BioFire® FilmArray® Gastrointestinal (GI) Panel tests stool in Cary Blair for the bacteria, viruses, and parasites commonly associated with gastroenteritis. Quickly identifying the probable pathogen can ensure appropriate treatment and patient management and help decrease infectious gastroenteritis, which can lead to severe illness or death.

Panel Menu

BACTERIA

Campylobacter (jejuni, coli, and upsaliensis) Clostridioides (Clostridium) difficile (toxin A/B) Plesiomonas shigelloides

Salmonella

Vibrio (parahaemolyticus, vulnificus, and cholerae) Vibrio cholerae

Yersinia enterocolitica

Diarrheagenic E.coli/Shigella

Enteroaggregative *E.coli* (EAEC)

Enteropathogenic *E.coli* (EPEC)

Enterotoxigenic E.coli (ETEC) It/st

Shiga-like toxin-producing *E.coli* (STEC) *stx1/stx2*

E.coli 0157

Shigella/Enteroinvasive E.coli (EIEC)

VIRUSES

Adenovirus F40/41 Astrovirus Norovirus GI/GII Rotavirus A

Sapovirus (I, II, IV, and V)

PARASITES

Cryptosporidium
Cyclospora cayetanensis
Entamoeba histolytica
Giardia lamblia



Sample Type: 200 μ L of uncentrifuged cerebrospinal fluid (CSF) CE-marked and US FDA-cleared

14 Targets in One Test

The BioFire® FilmArray® Meningitis/Encephalitis (ME) Panel identifies the most common viral, bacteria, and yeast pathogens that cause infections in the central nervous system which, in some cases, can be life-threatening. Rapidly identifying the probable cause of these potentially severe conditions can allow faster decisions on appropriate therapy.

Panel Menu

BACTERIA

Escherichia coli K1
Haemophilus influenzae
Listeria monocytogenes
Neisseria meningitidis
Streptococcus agalactiae
Streptococcus pneumoniae


VIRUSES

Cytomegalovirus (CMV)
Enterovirus (EV)
Herpes Simplex Virus 1(HSV-1)
Herpes Simplex Virus 2 (HSV-2)
Human Herpesvirus 6 (HHV-6)
Human Parechovirus (HPeV)
Varicella Zoster Virus (VZV)

YEAST

Cryptococcus neoformans/gattii







Sample Type: 200 µL positive blood culture media CE-marked and US FDA-cleared

43 Targets in One Test

The BioFire® Blood Culture Identification 2 (BCID2) Panel tests for the most common causes of bloodstream infections, including gram-positive, gram-negative, and yeast pathogens, and 10 antibiotic resistance genes. Quickly identifying the probable cause of bloodstream infections may help clinicians r the time to appropriate antimicrobial therapy and positively impact patient survival.

Panel Menu

GRAM-NEGATIVE BACTERIA

Acinetobacter calcoaceticusbaumannii complex

Bacteroides fragilis

Enterobacterales

Enterobacter cloacae complex

Escherichia coli

Klebsiella aerogenes

Klebsiella oxytoca

Klebsiella pneumoniae group

Proteus

Salmonella

Serratia marcescens

Haemophilus influenzae

Neisseria meningitidis

Pseudomonas aeruginosa Stenotrophomonas maltophilia

GRAM-POSITIVE BACTERIA

Enterococcus faecalis Enterococcus faecium

Listeria monocytogenes

Staphylococcus

Staphylococcus aureus

Staphylococcus epidermidis

Staphylococcus lugdunensis

Streptococcus

Streptococcus agalactiae

Streptococcus pneumoniae

Streptococcus pyogenes

YEAST

Candida albicans Candida auris

Candida glabrata

Candida krusei

Candida parapsilosis

Candida tropicalis

Cryptococcus neoformans/gattii

RESISTANCE GENES

Carbapenemases

IMP

KPC

OXA-48-like

NDM VIM

Colistin Resistance

mcr-1

ESBL

CTX-M

Methicillin Resistance


mecA/C

mecA/C and MREJ (MRSA)

vanA/B



Vancomycin Resistance



Peace of Mind All the Time.

First in Diagnostics. First in Customer Care.

bioMérieux has a skilled team dedicated to client success. Our customer support team provides global product support, solution training courses, LIS connectivity assistance, and instrument or chemistry related troubleshooting. We are committed to the speedy resolution of all technical issues.



International Support


For international BioFire technical assistance and support, please contact your local bioMérieux representative or distributor.



Help at Your Fingertips


With a complete suite of resources, our customers have access to everything they need for set-up, verification, and integration of the BioFire® FilmArray® System. Our website provides documents to assist with verification, EC Declarations of Conformity, and continuing education for all customers.

Visit **biofiredx.com** to find Advisory Notices, Information Sheets, Product Support Documents, and other resources.









bioMérieux S.A.

69280 Marcy l'Etoile

France

Tel.: +33 (0) 4 78 87 20 00

Fax: +33 (0) 4 78 87 20 90

www.biomerieux.com

Manufactured by:

BioFire Diagnostics, LLC

515 Colorow Drive, Salt Lake City,

UT 84108, USA

BioFire is wholly owned by bioMérieux.

www.biofiredx.com